By 2030, it is anticipated that the Japan HIV therapeutics market will reach a value of $1,100.42 Mn from $855.30 Mn in 2022, growing at a CAGR of 3.2% during 2022-30. The market is primarily dominated by local players such as Takeda Pharmaceutical, Eisai Co, and Daiichi Sankyo. The market is driven by innovation in research and development, increasing prevalence and reimbursement policies. The HIV therapeutics market in Japan is segmented by type, product, geography, end user, and distribution channel.
By 2030, it is anticipated that the Japan HIV therapeutics market will reach a value of $1,100.42 Mn from $855.30 Mn in 2022, growing at a CAGR of 3.2% during 2022-30.
In Japan, 1,076 more people were found to have HIV in 2020 compared to 1,236 in 2019, a decrease. The rapid decrease in the number of tests performed at public health facilities and other institutions in response to the coronavirus's spread appears to have had an impact on the outcomes. Japan is one of the wealthiest nations in the world, with a hard-working labor force and a sizable consumer market.
However, the East Asian nation does experience poverty, with a 15.4% poverty rate. HIV/AIDS is a significant issue in Japan, in addition to poverty. Particularly, a sizable proportion of HIV cases continue to go undiagnosed until they develop into AIDS. To change that and enhance HIV/AIDS treatments, Japan collaborates with the United Nations Programme on HIV/AIDS (UNAIDS). Currently, healthcare costs in Japan account for 10.7% of the GDP.
Market Growth Drivers Analysis
The Japanese government has made significant efforts to combat the HIV/AIDS epidemic in the nation, including offering free antiretroviral therapy (ART) to those in need through the public healthcare system. The Japanese government additionally funds initiatives related to HIV/AIDS in the private sector.
Market Restraints
The stigma and discrimination, along with other forms of social inequality and exclusion, are proving to be significant hindrances to the expansion of the HIV therapeutics market in Japan.
Key Players
May 2022: The Ministry of Health, Labour, and Welfare, Japan has approved the use of the first and only fully effective long-acting HIV treatment, Vocabria (cabotegravir injection and tablets), in combination with Johnson & Johnson's Rekambys (rilpivirine long-acting injectable suspension) and Edurant (rilpivirine tablets*), produced by Janssen Pharmaceutical Companies.
For the purpose of advancing HIV/AIDS research in Japan, the AIDS Research Center (ARC) was founded. The Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour, and Welfare (MHLW) are the regulatory bodies in Japan with authority over drugs.
The National Health Insurance regulates the cost of pharmaceuticals and biologicals. According to the Health Insurance Act, the MHLW establishes drug pricing standards. The MHLW consults with the Central Social Insurance Medical Council before announcing the pricing methodology and the cost of each drug.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Types (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.